Skin Clearance, Treatment Response Off-therapy, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

SKIN The Journal of Cutaneous Medicine

Topics

Chemistry

Dermatology

Medicine

Organic Chemistry

Immunology And Allergy

Show all topics

DOI

10.25251/skin.8.supp.460

License

CC-BY